Drug intelligence / Profile preview

trastuzumab + vinflunine

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of trastuzumab, a monoclonal antibody targeting HER2 receptors, and vinflunine, a microtubule inhibitor of the vinca alkaloid class. This combination has been studied primarily for the treatment of HER2-positive metastatic breast cancer. Trastuzumab binds to the HER2 receptor, inhibiting tumor cell growth and proliferation in HER2-overexpressing cancers, while vinflunine inhibits tubulin polymerization, arresting cell proliferation and leading to apoptotic death. Vinflunine also demonstrates anti-angiogenic and vascular disrupting activities.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on trastuzumab + vinflunine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trastuzumab + vinflunine.

Explore the full profile